“Milestone in Cancer therapy” Talimogene laherparepvec, the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes. The news came on October 27, 2015. The U.S. Food and Drug Administration approved novel Talimogene laherparepvec.
Talimogene laherparepvec programs viruses to attack only cancer cells and gives patients more humane options – potentially ‘a complete change in the game’ in treatment. CLINICAL PHARMACOLOGY: Mechanism of Action Talimogene laherparepvec has been genetically modified to replicate within tumors and to produce the immune stimulatory protein GM-CSF. Talimogene laherparepvec causes lysis of tumors, followed by release of tumor-derived antigens, which together with virally derived GM-CSF stimulate an immune response to kill melanoma cells in the tumour and elsewhere in the body & promote an antitumor immune…
